arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

FENNEC PHARMACEUTICALS INC.

FENC
$10.53 ▼ -0.48 (-4.36%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
118 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

FENNEC PHARMACEUTICALS INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $363.8M
Dividend Yield
Revenue Growth 85.2%
Op. Margin 9.7%
ROIC 4.0%
FCF / Share $0.00
Trailing P/E 175.5x
Price / Book 8.7x
FCF Yield 0.0%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

118-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$17.87M
↑ +85.2%
Net Income Profit after all expenses
$201.00K
— 0.0%
Operating Margin Operating profit as % of sales
9.7%
↑ +1333.8% 12th
FCF / Share Free cash flow per share
$0.00
↓ -97.9%
Long-Term Debt Long-term obligations
$19.38M
— +0.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
10
Returns
24
Financial Health
40
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 30 years · 118 quarters